These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28703720)

  • 1. Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients: Influence of Concomitant Antiepileptic Drugs.
    Yamamoto Y; Usui N; Nishida T; Takahashi Y; Imai K; Kagawa Y; Inoue Y
    Ther Drug Monit; 2017 Aug; 39(4):446-449. PubMed ID: 28703720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy.
    Yamamoto Y; Shiratani Y; Asai S; Usui N; Nishida T; Imai K; Kagawa Y; Takahashi Y
    Seizure; 2020 Dec; 83():181-186. PubMed ID: 33171342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perampanel Serum Concentrations in Adults With Epilepsy: Effect of Dose, Age, Sex, and Concomitant Anti-Epileptic Drugs.
    Patsalos PN; Gougoulaki M; Sander JW
    Ther Drug Monit; 2016 Jun; 38(3):358-64. PubMed ID: 26727625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Liquid Chromatography-Mass Spectrometry Assay for Determination of Perampanel and Concomitant Antiepileptic Drugs in the Plasma of Patients With Epilepsy Compared With a Fluorescent HPLC Assay.
    de Grazia U; DʼUrso A; Ranzato F; De Riva V; Contarato G; Billo G; Perini F; Galloni E
    Ther Drug Monit; 2018 Aug; 40(4):477-485. PubMed ID: 29746395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
    Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
    Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serum perampanel concentration profile after discontinuation of carbamazepine.
    Murugesu S; Okayama K; Yamamoto Y; Terada K; Takahashi Y
    Epileptic Disord; 2020 Aug; 22(4):455-461. PubMed ID: 32782230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Inflammation on the Pharmacokinetics of Perampanel.
    Yamamoto Y; Takahashi Y; Horino A; Usui N; Nishida T; Imai K; Kagawa Y; Inoue Y
    Ther Drug Monit; 2018 Dec; 40(6):725-729. PubMed ID: 30086086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
    Contin M; Riva R; Albani F; Avoni P; Baruzzi A
    Ther Drug Monit; 2002 Jun; 24(3):332-7. PubMed ID: 12021622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs.
    Markoula S; Teotonio R; Ratnaraj N; Duncan JS; Sander JW; Patsalos PN
    Ther Drug Monit; 2014 Aug; 36(4):494-8. PubMed ID: 24562047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
    Contin M; Albani F; Riva R; Candela C; Mohamed S; Baruzzi A
    Ther Drug Monit; 2013 Dec; 35(6):849-52. PubMed ID: 23942540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of an HPLC-UV Assay for the Therapeutic Monitoring of the New Antiepileptic Drug Perampanel in Human Plasma.
    Franco V; Marchiselli R; Fattore C; Tartara E; De Sarro G; Russo E; Perucca E
    Ther Drug Monit; 2016 Dec; 38(6):744-750. PubMed ID: 27753779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of saliva for perampanel therapeutic drug monitoring.
    Kim DY; Moon J; Shin YW; Lee ST; Jung KH; Park KI; Jung KY; Kim M; Lee S; Yu KS; Jang IJ; Song K; Chu K; Lee S
    Epilepsia; 2020 Jun; 61(6):1120-1128. PubMed ID: 32378757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy.
    Yamamoto Y; Takahashi Y; Imai K; Ikeda H; Takahashi M; Nakai M; Inoue Y; Kagawa Y
    Drug Metab Pharmacokinet; 2015 Jun; 30(3):214-20. PubMed ID: 25825021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
    Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J
    Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.
    Patsalos PN
    Epilepsia; 2015 Jan; 56(1):12-27. PubMed ID: 25495693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
    Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
    Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of valproic acid on perampanel pharmacokinetics in patients with epilepsy.
    Contin M; Bisulli F; Santucci M; Riva R; Tonon F; Mohamed S; Ferri L; Stipa C; Tinuper P;
    Epilepsia; 2018 Jul; 59(7):e103-e108. PubMed ID: 29897632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.